{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:52:58Z","timestamp":1777949578165,"version":"3.51.4"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"LLP National Research Oncology center, Astana, Kazakhstan"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: CD56 expression has been proposed as a prognostic and predictive biomarker in multiple myeloma. However, its clinical relevance in the context of modern induction therapy and autologous stem cell transplantation (ASCT) remains controversial. Methods: The researchers studied individuals with newly diagnosed multiple myeloma. CD56 expression was assessed by flow cytometry at diagnosis. Assessment was performed to determine patients\u2019 responses to induction therapy and to measure their progression-free and overall survival rates. Results: The study included 88 participants, of whom 68 (77%) were CD56-positive, and 20 (23%) were CD56-negative. The study results showed that CD56(\u2212) patients developed plasmacytomas at a 70% rate, while CD56(+) patients had a 46% rate (p = 0.055). A similar pattern was observed for extramedullary lesions (p = 0.006). The induction response rate was lower in CD56-negative patients than in CD56-positive patients (65% vs. 85%, p = 0.043). Patients who did not experience relapse received more CD34+ cells (11.9 \u00b1 5.71 vs. 9.29 \u00b1 2.57 \u00d7 106\/kg, p = 0.012) and had higher post-transplant response rates (91% vs. 63%, p = 0.002). The patients who received induction treatment before their disease showed better survival outcomes than patients who did not respond to treatment (90.2% vs. 87.1%, p = 0.029) and patients who did not experience relapse (92.7% vs. 85.0%, p = 0.022). CD56 status did not affect survival outcomes. Conclusions: CD56 expression is associated with disease burden and response to induction therapy in multiple myeloma, supporting its role as an early disease-modifying factor. However, its prognostic value appears limited in patients receiving high-dose chemotherapy with ASCT, suggesting that intensive treatment may mitigate the adverse impact of CD56 negativity.<\/jats:p>","DOI":"10.3390\/jcm15093492","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:12:09Z","timestamp":1777857129000},"page":"3492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Role of CD56 as an Immunophenotypic Marker in the Clinical Course of Multiple Myeloma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9281-4041","authenticated-orcid":false,"given":"Azat","family":"Karabekov","sequence":"first","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vadim","family":"Kemaikin","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhandos","family":"Burkitbayev","sequence":"additional","affiliation":[{"name":"National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1001-1374","authenticated-orcid":false,"given":"Gulnur","family":"Zhakhina","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nazarbayev University School of Medicine, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aigerim","family":"Sipenova","sequence":"additional","affiliation":[{"name":"Science Management Department, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inna","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, Republican Specialized Scientific and Practical Center of Hematology, Tashkent 100059, Uzbekistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7133-6724","authenticated-orcid":false,"given":"Ulbolsyn","family":"Orumbayeva","sequence":"additional","affiliation":[{"name":"University Medical Center CF, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6849-4273","authenticated-orcid":false,"given":"Zhuldyz","family":"Iskakova","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Ibragimova","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazym","family":"Temir","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulnur","family":"Mamyr","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Kolesnikova","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariza","family":"Shokubaeva","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbota","family":"Tursyn","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4955-0542","authenticated-orcid":false,"given":"Meiramgul","family":"Yussupova","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidana","family":"Shalkarbekova","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayagul","family":"Ainabay","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandr","family":"Kolesnev","sequence":"additional","affiliation":[{"name":"Department of Oncohematology and Bone Marrow Transplantation, National Research Oncology Center LLP, Astana 010000, Kazakhstan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/carcin\/bgaa037","article-title":"Genotype\u2013immunophenotype analysis reveals the immunogenomic subtype and prognosis of multiple myeloma","volume":"41","author":"Wang","year":"2020","journal-title":"Carcinogenesis"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"6248","DOI":"10.15419\/bmrat.v11i3.870","article-title":"Immunophenotypic Expression and its Association with Prognostic Factors, Clinical Stages, and Clinical Profiles in Newly Diagnosed Patients with Plasma Cell Myeloma: Insights from Two Tertiary Care Centers","volume":"11","author":"Ismail","year":"2024","journal-title":"Biomed. Res. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1179\/1607845415Y.0000000010","article-title":"The prognostic impact of multiparameter flow cytometry immunophenotyping and cytogenetic aberrancies in patients with multiple myeloma","volume":"21","author":"Guo","year":"2016","journal-title":"Hematology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"IJH39","DOI":"10.2217\/ijh-2021-0017","article-title":"Adhesion molecules in multiple myeloma oncogenesis and targeted therapy","volume":"11","author":"Zerdan","year":"2022","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Solimando, A.G., Malerba, E., Leone, P., Prete, M., Terragna, C., Cavo, M., and Racanelli, V. (2022). Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.973836"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Fotiou, D., and Katodritou, E. (2025). From Biology to Clinical Practice: The Bone Marrow Microenvironment in Multiple Myeloma. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020327"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153567","DOI":"10.1016\/j.prp.2021.153567","article-title":"CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome","volume":"225","author":"Koumpis","year":"2021","journal-title":"Pathol.-Res. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_13","unstructured":"International Myeloma Working Group (2014). International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma, International Myeloma Working Group."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Leonardos, D., Benetatos, L., Apostolidou, E., Koumpis, E., Dova, L., Kapsali, E., Kotsianidis, I., and Hatzimichael, E. (2025). Applications of multiparameter flow cytometry in the diagnosis, prognosis, and monitoring of multiple myeloma patients. Diseases, 13.","DOI":"10.20944\/preprints202508.0725.v1"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Ho, M., Paruzzo, L., Minehart, J., Nabar, N., Noll, J.H., Luo, T., Garfall, A., and Zanwar, S. (2025). Extramedullary multiple myeloma: Challenges and opportunities. Curr. Oncol., 32.","DOI":"10.3390\/curroncol32030182"},{"key":"ref_19","first-page":"777","article-title":"Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors","volume":"31","author":"Wang","year":"2023","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-024-01051-5","article-title":"CD56 expression predicts response to Daratumumab-based regimens","volume":"14","author":"Robinette","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.4103\/ijh.ijh_75_25","article-title":"The role of CD319, CD117, CD28, CD49e, CD56, and CD44 expression as diagnostic and prognostic markers in multiple myeloma","volume":"14","year":"2025","journal-title":"Iraqi J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.18632\/oncotarget.28350","article-title":"To be or not to be: The role of CD56 in multiple myeloma","volume":"14","author":"Cottini","year":"2023","journal-title":"Oncotarget"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106157","DOI":"10.1016\/j.htct.2025.106157","article-title":"CD56-Negative Conjunctival Solitary Extramedullary Plasmacytoma with Bence\u2013Jones Lambda: Organ-Sparing Therapy and Durable Remission in a Young Adult","volume":"47","year":"2025","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12308-025-00651-9","article-title":"Plasmablastic plasmacytoma followed by a plasmacytic plasma cell myeloma: Insights into discordant extramedullary transformation\u2014A case report and literature review","volume":"18","author":"Abdolahi","year":"2025","journal-title":"J. Hematop."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.12788\/cutis.0901","article-title":"Aberrant Expression of CD56 in Metastatic Malignant Melanoma","volume":"112","author":"White","year":"2023","journal-title":"Cutis"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Geng, C., Zhou, H., Wang, H., Li, Y., Leng, Y., Zhang, Z., Jian, Y., Yang, G., and Chen, W. (2022). Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10382-0"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Yoshida, T., Ri, M., Kinoshita, S., Narita, T., Totani, H., Ashour, R., Ito, A., Kusumoto, S., Ishida, T., and Komatsu, H. (2018). Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0196780"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000489483","article-title":"CD56 expression is an important prognostic factor in multiple myeloma even with bortezomib induction","volume":"139","author":"Skerget","year":"2018","journal-title":"Acta Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/sj.bmt.1705857","article-title":"Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t (11; 14)","volume":"40","author":"Hundemer","year":"2007","journal-title":"Bone Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/16078454.2021.2019365","article-title":"Prognostic significance of CD56 expression in patients with multiple myeloma: A meta-analysis","volume":"27","author":"Zhang","year":"2022","journal-title":"Hematology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/10428194.2025.2604564","article-title":"Impact of CD34+ cell infusion dose on immune reconstitution and survival in multiple myeloma after autologous stem cell transplantation","volume":"67","author":"Zhang","year":"2026","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41408-024-01165-w","article-title":"Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation","volume":"14","author":"Pasvolsky","year":"2024","journal-title":"Blood Cancer J."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:32:21Z","timestamp":1777858341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/9\/3492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15093492"],"URL":"https:\/\/doi.org\/10.3390\/jcm15093492","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]}}}